Genetic predisposition to prostate cancer: Update and future perspectives
- PMID: 24996773
- DOI: 10.1016/j.urolonc.2014.04.021
Genetic predisposition to prostate cancer: Update and future perspectives
Abstract
Objective: Prostate cancer is the second most frequent cancer in men worldwide and kills over 250,000 men worldwide every year. Prostate cancer is a heterogeneous disease at the clinical and the molecular level. The Scandinavian Twin Registry Study demonstrated that in contrast to most malignancies where environment was the overriding influence, heritable factors account for more than fifty percent of prostate cancers.
Methods and materials: We review the literature on prostate cancer risk variants (rare and common) including SNPs and Copy Number Variants (CNVs) and discuss the potential implications of significant variants for prostate cancer patient care.
Results: The search for prostate cancer susceptibility genes has included both family-based studies and case-control studies utilizing a variety of approaches from array-based to sequencing-based studies. A major challenge is to identify genetic variants associated with more aggressive, potentially lethal prostate cancer and to understand their role in the progression of the disease.
Conclusion: Future risk models useful in the clinical setting will likely incorporate several risk loci rather than single variants and may be dependent on an individual patient's ethnic background.
Keywords: CNV; Common variants; Prostate cancer risk; Rare variants; SNP.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Perspective: prostate cancer susceptibility genes.Endocrinology. 2002 Jun;143(6):2029-40. doi: 10.1210/endo.143.6.8890. Endocrinology. 2002. PMID: 12021166 Review.
-
Prostate cancer risk variants are not associated with disease progression.Prostate. 2012 Jan;72(1):30-9. doi: 10.1002/pros.21403. Epub 2011 Apr 25. Prostate. 2012. PMID: 21520160
-
Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features.Eur Rev Med Pharmacol Sci. 2010 Jan;14(1):31-41. Eur Rev Med Pharmacol Sci. 2010. PMID: 20184087 Review.
-
Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.Gene. 2014 Jan 1;533(1):86-93. doi: 10.1016/j.gene.2013.09.119. Epub 2013 Oct 9. Gene. 2014. PMID: 24120391
-
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.J Natl Cancer Inst. 2005 Apr 6;97(7):525-32. doi: 10.1093/jnci/dji070. J Natl Cancer Inst. 2005. PMID: 15812078
Cited by
-
In-silico identification and functional validation of allele-dependent AR enhancers.Oncotarget. 2015 Mar 10;6(7):4816-28. doi: 10.18632/oncotarget.3019. Oncotarget. 2015. PMID: 25693204 Free PMC article.
-
Emerging Relationship between the Gut Microbiome and Prostate Cancer.World J Mens Health. 2023 Oct;41(4):759-768. doi: 10.5534/wjmh.220202. Epub 2023 Feb 22. World J Mens Health. 2023. PMID: 36876743 Free PMC article. Review.
-
Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis.BMC Cancer. 2016 Aug 23;16(1):674. doi: 10.1186/s12885-016-2722-2. BMC Cancer. 2016. PMID: 27553621 Free PMC article.
-
Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants.Cancer Res. 2019 Jul 1;79(13):3192-3204. doi: 10.1158/0008-5472.CAN-18-3536. Epub 2019 May 17. Cancer Res. 2019. PMID: 31101764 Free PMC article.
-
Editorial - From robot to molecule, the behavior.Int Braz J Urol. 2016 May-Jun;42(3):409-12. doi: 10.1590/S1677-5538.IBJU.2016.03.02. Int Braz J Urol. 2016. PMID: 27286100 Free PMC article. No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical